Eight weeks of CBD-rich cannabis treatment induced significant clinical and QOL improvement without significant changes in inflammatory parameters or endoscopic scores. The oral CBD-rich cannabis extract was well absorbed. Until further studies are available, cannabis treatment in Crohn's disease sh … Is cannabis the answer for people with Crohn’s and ulcerative colitis? The evidence is still out on its safety and effectiveness.
Oral CBD-rich Cannabis Induces Clinical but Not Endoscopic Response in Patients with Crohn’s Disease, a Randomised Controlled Trial
Aims: Despite reports that medical cannabis improves symptoms in Crohn’s disease [CD], controlled studies evaluating disease response are lacking. This study assessed the effect of cannabidiol [CBD]-rich cannabis oil for induction of remission in CD.
Methods: In a double-blind, randomised, placebo-controlled, single-centre trial, patients received orally either cannabis oil containing160/40 mg/ml cannabidiol/tetrahydrocannabinol [CBD/THC] or placebo for 8 weeks. Disease parameters, including the CD activity index [CDAI], and simple endoscopic score for CD [SES-CD], were assessed before and after treatment. In a subgroup of patients, blood samples were collected for CBD and THC plasma levels.
Conclusions: Eight weeks of CBD-rich cannabis treatment induced significant clinical and QOL improvement without significant changes in inflammatory parameters or endoscopic scores. The oral CBD-rich cannabis extract was well absorbed. Until further studies are available, cannabis treatment in Crohn’s disease should be used only in the context of clinical trials.
Keywords: Crohn’s disease; cannabidiol; cannabis.
© The Author(s) 2021. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: [email protected]
Gianotti RJ, Cheifetz AS. Gianotti RJ, et al. J Crohns Colitis. 2021 Nov 8;15(11):1785-1786. doi: 10.1093/ecco-jcc/jjab091. J Crohns Colitis. 2021. PMID: 34137450 No abstract available.
Kafil TS, Nguyen TM, MacDonald JK, Chande N. Kafil TS, et al. Cochrane Database Syst Rev. 2018 Nov 8;11(11):CD012853. doi: 10.1002/14651858.CD012853.pub2. Cochrane Database Syst Rev. 2018. PMID: 30407616 Free PMC article.
Naftali T, Bar-Lev Schleider L, Dotan I, Lansky EP, Sklerovsky Benjaminov F, Konikoff FM. Naftali T, et al. Clin Gastroenterol Hepatol. 2013 Oct;11(10):1276-1280.e1. doi: 10.1016/j.cgh.2013.04.034. Epub 2013 May 4. Clin Gastroenterol Hepatol. 2013. PMID: 23648372 Clinical Trial.
Naftali T, Mechulam R, Marii A, Gabay G, Stein A, Bronshtain M, Laish I, Benjaminov F, Konikoff FM. Naftali T, et al. Dig Dis Sci. 2017 Jun;62(6):1615-1620. doi: 10.1007/s10620-017-4540-z. Epub 2017 Mar 27. Dig Dis Sci. 2017. PMID: 28349233 Clinical Trial.
Hardy J, Haywood A, Gogna G, Martin J, Yates P, Greer R, Good P. Hardy J, et al. Trials. 2020 Jul 6;21(1):611. doi: 10.1186/s13063-020-04541-6. Trials. 2020. PMID: 32631447 Free PMC article.
Kafil TS, Nguyen TM, MacDonald JK, Chande N. Kafil TS, et al. Inflamm Bowel Dis. 2020 Mar 4;26(4):502-509. doi: 10.1093/ibd/izz233. Inflamm Bowel Dis. 2020. PMID: 31613959 Review.
Bilbao A, Spanagel R. Bilbao A, et al. BMC Med. 2022 Aug 19;20(1):259. doi: 10.1186/s12916-022-02459-1. BMC Med. 2022. PMID: 35982439 Free PMC article. Review.
Baratta F, Pignata I, Ravetto Enri L, Brusa P. Baratta F, et al. Front Pharmacol. 2022 May 25;13:888903. doi: 10.3389/fphar.2022.888903. eCollection 2022. Front Pharmacol. 2022. PMID: 35694246 Free PMC article.
De Conno B, Pesce M, Chiurazzi M, Andreozzi M, Rurgo S, Corpetti C, Seguella L, Del Re A, Palenca I, Esposito G, Sarnelli G. De Conno B, et al. Foods. 2022 Apr 4;11(7):1044. doi: 10.3390/foods11071044. Foods. 2022. PMID: 35407131 Free PMC article. Review.
Tartakover Matalon S, Azar S, Meiri D, Hadar R, Nemirovski A, Abu Jabal N, Konikoff FM, Drucker L, Tam J, Naftali T. Tartakover Matalon S, et al. Front Endocrinol (Lausanne). 2021 Aug 31;12:685289. doi: 10.3389/fendo.2021.685289. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34531823 Free PMC article. Clinical Trial.
Buckley MC, Kumar A, Swaminath A. Buckley MC, et al. Adv Ther. 2021 Jul;38(7):4152-4161. doi: 10.1007/s12325-021-01805-8. Epub 2021 Jun 10. Adv Ther. 2021. PMID: 34110607 Free PMC article. Review.
Does cannabis offer new hope for folks with Crohn’s disease and ulcerative colitis?
Stomach pain, cramps, diarrhea, fatigue, rectal bleeding, fever, weight loss—these are just a few symptoms that are all too familiar to people with inflammatory bowel disease (IBD) (1-4). While people with IBD often feel embarrassed about their condition, there is no shame in it. Talking about IBD can lead to finding better ways to cope.
IBD is an umbrella term that describes chronic inflammatory conditions that affect the digestive tract—which includes the mouth, esophagus, stomach, and the small and large intestines (1-5). Crohn’s disease and ulcerative colitis are the most common forms of IBD (6). In North America, over 1.6 million people live with IBD (1;7-8), including around 270,000 Canadians—projected to be 400,000 by 2030 (9). And you guessed it…the fastest growing group of Canadians with IBD is adults aged 65 years old and over (9;10).
The cause of IBD is still a mystery, but it is thought to arise when environmental factors (e.g., infections, antibiotics, etc.) prompt the immune system to mistakenly attack microorganisms and food in the gut, producing inflammation in the digestive tract. Genetics may also play a role in increasing the risk of IBD (1-4;11). Typically, the disease alternates between periods of inactivity (a.k.a. remission) and periods when symptoms flare-up (a.k.a. relapse) (2-4).
Unfortunately, there is no cure for IBD. Instead, go-to medications often aim to reduce inflammation or suppress the immune system to get and keep people in remission (2-5). Many of these medications can come with potentially serious side effects, such as lymphoma, non-melanoma skin cancers, and liver issues (9).
One popular and highly debated alternative treatment option is cannabis (2;4). With cannabis touted as a one stop-shop for many of our medical needs, and its increasing accessibility through legalization, where does the evidence stand on its use for Crohn’s and ulcerative colitis, specifically?
What the research tells us
Two recent systematic reviews —one including patients with active Crohn’s (2) and the other including patients with active ulcerative colitis (4)—looked at the effect of cannabis cigarettes and cannabis oil on outcomes such as disease remission or activity, inflammation, side effects, and quality of life.
When reported on, neither review found that cannabis cigarettes or cannabis oil induced remission in patients with active disease or helped with inflammation (2;4). In both Crohn’s and ulcerative colitis, cannabis cigarettes led to a reduction in disease activity (2;4), but in Crohn’s patients, this was accompanied by an increase in mild side effects such as memory loss, drowsiness, confusion, dizziness, and trouble concentrating (2). Cannabis oil produced potentially meaningful increases in quality of life in both types of IBD (2;4), but in patients with ulcerative colitis, this strategy was associated with mild to moderately severe side effects such as headache, tiredness, dizziness, nausea, and trouble concentrating (4).
So, what should patients and caregivers affected by Crohn’s and ulcerative colitis make of these findings?
Ultimately, the evidence-base around the use of cannabis and cannabis oil for Crohn’s or ulcerative colitis is not of high quality. This means, at this time, no concrete conclusions about the effectiveness or safety of cannabis and cannabis oil can be made. Ideally, future research will include a larger number of participants, account for different disease statuses (e.g., active and inactive), and evaluate different types/doses of cannabis (2;4).
If you’re considering using cannabis or cannabis oil to treat your Crohn’s or ulcerative colitis, reach out to your health care provider to help you navigate the potential harms and benefits and factor in where the current evidence lies.